Aptus Biotech is developing a ultra sensitive detection and diagnostics platform based on aptamer technology. The AptaDetect system is compatible with equipment installed in standard laboratories and can detect virtually any target. AptaDetect can be applied in Health diagnostics, and also in Environment or Agriculture-Food testing.
AptusBiotech collaborates with CAB-CSIC, IRYCIS (Institute of Biomedical Research, University Hospital Ramón y Cajal) and the private company Vircell on the development and validation of a diagnostic and genotyping system for Hepatitis C (HCV), using the AptaDetect technology.
AptaVirus-HIV: aptamers for Human Immunodeficiency
Aptamer-based molecules that efficiently inhibits the replication of all subtype groups of Human Immunodeficiency Virus (HIV-1). Their mechanism of action is based on the binding to the virus genome and inhibition of its replication. These aptamers reduce viral load between 70-80% and show lower toxicity. Besides, the virus will have more difficulty to generate resistant mutations unlike the drugs used in current therapeutic approaches. Aptus collaborates with the Institute of Parasitology and Biomedicine "López-Neyra" (IPBLN-CSIC) and the Centro de Astrobiología (CSIC-INTA).
AptA4: aptamers against ApoAIV
AptusBiotech collaborates on the development of aptamers against ApoAIV protein, in order to detect and quantify the presence of the protein in blood samples from patients. The project also involves the University of Barcelona, the IRYCIS (Institute of Biomedical Research, University Hospital Ramón y Cajal), IGEN Biotech, Biosystems and Janus Development.
AptA4 is part of a INNPACTO project, supported by the MINECO (Spanish Ministry of Economy)
ApTLR: aptamers against Toll-like receptors (TLR)
The involvement of innate immunity and in particular the TLRs in many diseases has produced a growing interest in the development of agonists and antagonists of these receptors as therapeutic tools. In collaboration with the IRYCIS (Instituto de Investigación Biomédica del Hospital Universitario Ramón y Cajal) and the Neurovascular Research Unit from the Universidad Complutense, Aptus has developed drug candidates based on aptamers and is currently validating its therapeutic potential. �
This project has been supported by the MINECO (Spanish Ministry of Economy) RETOS-COLABORACION program. �